Navigation Links
Large-scale genomic analysis of prostate cancer unveiled
Date:6/25/2010

NEW YORK, June 24, 2010A unique collaboration among physician-scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) has yielded the most comprehensive genomic analysis of prostate cancer to date. "Genomic studies in other cancer types have resulted in new drug targets and strategies to classify patients into clinically meaningful subgroups that improve treatment decisions," said senior study author Charles Sawyers, Chair of the Human Oncology and Pathogenesis Program at MSKCC and a HHMI investigator. "This first -ever database of its type brings us one step closer to achieving that goal in prostate cancer."

The study, published early online on June 24 in the journal Cancer Cell, provides a previously unavailable genomic analysis whose scope and size offers new insight leading to more effective diagnostic tests as well as future treatment options for prostate cancer patients.

"We have used all of our expertise and resources to complete a large-scale study of the changes in the genomes of patients' prostate cancers," says Dr. Sawyers, who explains that prostate tumor cells are very difficult to work with despite the fact that prostate cancer is the most common cancer in men. Consequently, there have been fewer genomic studies in prostate cancer compared to other tumor types such as lung cancer. "The ability to collect and analyze these tumor samples is a testament to the collaboration and expertise across many disciplines."

The MSKCC team, composed of members of the Human Oncology and Pathogenesis Program, urology, medicine and genitourinary oncology services, pathology, computational biology, and statistics departments, used an integrated, comprehensive approach to analyze 218 primary and metastatic samples and 12 cell lines. All samples were procured from patients treated by radical prostatectomy at MSKCC. The analysis revealed a much higher frequency of alterations in the androgen receptor pathway than previously suspected. Also, the pattern of DNA copy number alterations identified defined subsets of low-and high-risk disease beyond what is revealed by Gleason score.

"One of the holy grails of prostate cancer is to identify which tumors need to be aggressively treated and which don't," said Dr. Sawyers. "Ultimately, what we have learned could lead to the creation of a genetic-based test to determine which prostate cancers might become more virulent and require aggressive treatment and which tumors may not." According to Dr. Sawyers, "This data clarifies the role of several known cancer pathways and provides important clues into others. We have gained insight into the importance of androgen receptor statusand why some men respond to hormone therapy and others don't."


'/>"/>

Contact: Jeanne D'Agostino
dagostij@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Confronting infectious disease threats at large-scale international events
2. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
3. Breast Cancer Patients Often Confused by Genomic Testing
4. Improvements needed in genomic test result discussions
5. Lawrence Berkeley National Laboratory and OpenHelixTM Announce an Updated Free Tutorial Suite for VISTA: Tools for Comparative Genomics
6. SeqWright Advances Genomic Discovery With Isilon IQ
7. Researchers chart genomic map spanning over 2 dozen cancers
8. UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line
9. Genomic surveillance of pandemic H1N1
10. The Institut Curie and Ipsogen Sign a Scientific Collaboration Agreement Relating to the Genomic Grade, a Molecular Diagnostic Tool for Breast Cancer
11. NeoGenomics Announces Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, LLC ... Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February 24, ... honored to have Amy E. Herman present at this year’s conference, her unprecedented ...
(Date:12/5/2016)... ... December 05, 2016 , ... U.S. Apple Association (USApple) ... part of the second annual Apples for Education: Buy an Apple, Help a ... providing healthy food for students to take home to their families; solar technology to ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson who has ... Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , The sessions ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... way to ensure moisture measurements are consistently correct. However, regular performance testing ... Now, METTLER TOLEDO offers a solution: SmartCal™ . This innovative test ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAKE, N.J. , Dec. 5, 2016 ... perampanel presented at the 2016 Annual Meeting of the ... as FYCOMPA® CIII, is indicated as an adjunctive therapy ... or without secondarily generalized seizures and primary generalized tonic-clonic ... years of age and older. Please see Important Safety ...
(Date:12/5/2016)... , December 5, 2016 PharmaBoardroom today releases ... . ... This report offers companies, investors, policymakers, and stakeholders crucial insight ... of Europe , home to some of the world,s ... pharmaceutical companies in Novartis and Roche, and with a number one ranking ...
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
Breaking Medicine Technology: